An international study led by University of Leicester researchers has indicated that vaccination will be the best way to protect people in the event of the next influenza pandemic, but added that each person would need two doses.
Influenza pandemic occurs when a new influenza strain emerges (one to which humans have no immunity), mutates and spreads globally as a virus.
It is not feasible to predict the actual pandemic influenza strain, but global health authorities have identified H5N1 avian influenza as a strain with the greatest pandemic potential in humans.
"In addition, it generally takes two doses of vaccine to give a good response, so if a pandemic occurred it would take some time to produce vaccine and then administer 2 doses to protect people. Therefore stockpiling of vaccines has been suggested to overcome some of these difficulties. However, subjects will still require 2 doses to generate protection and if the pandemic spreads rapidly this could be challenging to deliver," Stephenson.
For the study, the researchers looked at boosting those people who were vaccinated up to 7 years ago in the first H5 vaccine trials conducted in Leicester with a new updated H5 vaccine, in comparison to vaccinating subjects for the first time.
"We have found that a single low dose booster vaccine, given 7 years later, generated a very rapid response and within 1 week of vaccination, over 80 percent subjects had an excellent response to all strains of the H5 virus. In comparison, the unprimed subjects who were vaccinated for the first time needed two doses of vaccine and achieved protective levels of antibody after 6 weeks as expected," the authors said.
The results indicate that regardless of which avian strain individuals are originally primed with, they are quickly protected against a broad range of avian strains following their booster vaccine, even strains they were not initially inoculated against.
These results potentially provide a rationale to prevent pandemic influenza by proactively immunizing the public with stockpiled pre-pandemic vaccines.
The study is published in the New England Journal of Medicine on Oct 9.